OBJECTIVES The aim of this study is to compare the cost effectiveness of oral antiviral treatment strategies in CHB for Turkey using lamuvidine,telbuvidine,entecavir, and tenofovir as medications. METHODS The analysis was conducted using Markov model. Inadequate response or resistance after receiving 12 months of the treatment with entecavir and telbivudine were compared to the results found from switching from entecavir to tenofovir or from switching from telbuvidine to tenofovir. In additional, inadequate response or resistance after receiving 6 months of the treatment for lamivudine was compared to the results found from switching from lamivudine to tenofovir. The model duration was constructed to evaluate a treatment strategy duration of 40 years. Years of Potential Life Lost(YPLL) was used as the health outcome. An incremental cost-effectiveness ratio(ICER) analysis of the results was conducted. RESULTS In a life time period, the lowest YPLL and the cost of treatment were calculated for the NS.Tenofovir treatment with 0.54 years and 37,213.75 TL.Depending on the results,the lowest YPLL and the cost of treatment were served by NS.Tenofovir treatment with 2.06 years and 276,468.45 TL.The highest YPLL and the cost of treatment were calculated for the NS.The ICER analysis found that all treatment strategies were dominated by NS.Tenofovir and S.Entecavir.Only these two treatment strategies were found to be cost-effective. CONCLUSIONS The cost of providing 40 years of treatment for patients with CHB,if reimbursement agencies includes Tenofovir and Entecavir as part of the first line treatment strategy for CHB,it can be expected that this approach would result in a positive contribution to the health budget in Turkey.